Today: 7 February 2026
Subscribe
Browse Category

Earnings Reports News 4 February 2026

UBS stock slides 5% after earnings as buyback and U.S. wealth outflows bite

UBS stock slides 5% after earnings as buyback and U.S. wealth outflows bite

UBS shares fell 5.2% to 35.16 Swiss francs in Zurich after the bank reported a 56% rise in fourth-quarter profit and announced a $3 billion share buyback for 2026. CFO Todd Tuckner warned outflows from the U.S. wealth unit will likely accelerate as advisers leave. UBS’s full-year net profit reached $7.8 billion. The bank’s capital return plans remain tied to pending Swiss regulatory changes.
4 February 2026
··
S&P Global stock tumbled 11% on AI disruption fears — what to watch before earnings

S&P Global stock tumbled 11% on AI disruption fears — what to watch before earnings

S&P Global shares fell 11.3% premarket Wednesday to $468.21 after a broad selloff in data and analytics stocks, triggered by fears that new generative AI tools could erode pricing power. The company recently raised its dividend and confirmed plans to spin off its Mobility division, now branded as Mobility Global, Inc. Gartner, Intuit, and Equifax also dropped over 10%. The S&P 500 closed down 0.84% Tuesday.
4 February 2026
··
Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly shares fell 0.5% to $998.50 in premarket trading Wednesday after a 4% drop Tuesday, following Novo Nordisk’s warning of up to a 13% drop in 2026 sales and profits. Novo cut prices and launched an oral Wegovy, while Lilly plans to cap higher-dose obesity drug prices at $399 per month for repeat cash buyers. Investors await Lilly’s Q4 results and comments on pricing and competition.
4 February 2026
···
SMCI stock steadies premarket after Super Micro lifts FY2026 sales outlook to $40 billion

SMCI stock steadies premarket after Super Micro lifts FY2026 sales outlook to $40 billion

Super Micro Computer raised its fiscal 2026 revenue forecast to at least $40 billion, up from $36 billion. Shares edged up 0.1% to $29.67 premarket after December-quarter sales hit $12.7 billion, but gross margin fell to 6.3% from 9.3%. Management cited tariffs, memory shortages, and rising costs as margin pressures. The company projects at least $12.3 billion in sales for the March quarter.
4 February 2026
···
AMD stock price slides in premarket as forecast hints at softer quarter, spotlight stays on China chip sales

AMD stock price slides in premarket as forecast hints at softer quarter, spotlight stays on China chip sales

AMD shares fell 7.6% in premarket trading Wednesday after the company forecast a sequential revenue decline and projected first-quarter sales near $9.8 billion. The outlook included $100 million in MI308 AI chip sales to China, with management citing U.S. export controls as a key uncertainty. Data-center revenue rose 39% to $5.4 billion last quarter, but investors focused on AMD’s 55% adjusted gross margin versus Nvidia’s higher target.
4 February 2026
··
Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk stock hammered as Ozempic maker warns 2026 sales may fall up to 13%

Novo Nordisk warned adjusted sales and operating profit may fall 5% to 13% in 2026, citing U.S. price cuts and rising competition from Eli Lilly. Shares plunged 18% in early Copenhagen trading. CEO Mike Doustdar called the U.S. price reductions for Wegovy “painful.” Novo also flagged patent expiries and pressure from compounded GLP-1 drugs.
4 February 2026
···
GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK stock swings after earnings as new CEO Luke Miels sets softer 2026 outlook

GSK shares rose 1.4% Wednesday morning after new CEO Luke Miels issued a 2026 outlook projecting slower sales growth and warning of possible weakness in vaccines and general medicines. The company reported 2025 sales up 7% to £32.67 billion and forecast 2026 turnover growth of 3% to 5%. Investors remain focused on GSK’s ability to manage looming HIV patent expirations.
4 February 2026
···
LSEG share price extends AI-driven slide as investors brace for BoE, earnings

LSEG share price extends AI-driven slide as investors brace for BoE, earnings

London Stock Exchange Group shares fell 1.3% to 7,086 pence by 08:07 GMT Wednesday, after plunging 12.7% the previous day. The drop followed new AI tools from Anthropic, raising fears over LSEG’s data and analytics business. Trading volume on Tuesday hit 3.2 million shares, more than double the 50-day average. LSEG disclosed a fresh buyback as investors await the Bank of England’s Feb. 5 decision and earnings later this month.
4 February 2026
····
Keppel stock price ticks higher after S$600 million contract haul as Feb 5 results loom

Keppel stock price ticks higher after S$600 million contract haul as Feb 5 results loom

Keppel Ltd shares rose 0.46% to S$10.94 in Singapore on Wednesday after its infrastructure arm secured about S$600 million in new contracts, pushing its long-term backlog past S$7.1 billion. The company will release its second-half and full-year 2025 results before market open on Thursday, with investors watching for updates on contract wins and recurring service income.
4 February 2026
··
1 … 21 22 23 24 25 … 337

Stock Market Today

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop